GSK-3 beta regulates tumor growth and angiogenesis in human glioma cells

Peng Zhao,Qi Li,Zhumei Shi,Charlie Li,Lin Wang,Xue Liu,Chengfei Jiang,Xu Qian,Yongping You,Ning Liu,Ling-Zhi Liu,Lianshu Ding,Bing-Hua Jiang
DOI: https://doi.org/10.18632/oncotarget.5043
2015-01-01
Oncotarget
Abstract:Background: Glioma accounts for the majority of primary malignant brain tumors in adults. Methods: Glioma specimens and normal brain tissues were analyzed for the expression levels of GSK-3 beta and p-GSK-3 beta (Ser9) by tissue microarray analysis (TMA) and Western blotting. Glioma cells over-expressing GSK-3 beta were used to analyze biological functions both in vitro and in vivo. Results: The levels of p-GSK-3 beta (Ser9), but not total GSK-3 beta, are significantly up-regulated in glioma tissues compared to normal tissues, and are significantly correlated with the glioma grades. Ectopic expression of GSK-3 beta decreased the phosphorylation levels of mTOR and p70S6K1; and inhibited beta-catenin, HIF-1 alpha and VEGF expression. Forced expression of GSK-3 beta in glioma cells significantly inhibited both tumor growth and angiogenesis in vivo. Conclusions: These results reveal that GSK-3 beta regulates mTOR/p70S6K1 signaling pathway and inhibits glioma progression in vivo; its inactivation via p-GSK-3 beta (Ser9) is associated with glioma development, which is new mechanism that may be helpful in developing GSK-3 beta-based treatment of glioma in the future.
What problem does this paper attempt to address?